270 related articles for article (PubMed ID: 26423694)
1. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
Huynh MV; Campbell SL
Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
[TBL] [Abstract][Full Text] [Related]
2. Past, Present, and Future of Targeting Ras for Cancer Therapies.
Tan Z; Zhang S
Mini Rev Med Chem; 2016; 16(5):345-57. PubMed ID: 26423695
[TBL] [Abstract][Full Text] [Related]
3. Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules.
Goody RS; Müller MP; Rauh D
Cell Chem Biol; 2019 Oct; 26(10):1338-1348. PubMed ID: 31378709
[TBL] [Abstract][Full Text] [Related]
4. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
Molina-Arcas M; Samani A; Downward J
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of RAS: New hope for drugging the "undruggable".
Khan I; Rhett JM; O'Bryan JP
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118570. PubMed ID: 31678118
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule modulation of Ras signaling.
Spiegel J; Cromm PM; Zimmermann G; Grossmann TN; Waldmann H
Nat Chem Biol; 2014 Aug; 10(8):613-22. PubMed ID: 24929527
[TBL] [Abstract][Full Text] [Related]
7. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
9. Drugging K-Ras
Ni D; Li X; He X; Zhang H; Zhang J; Lu S
Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.
Chuang HC; Huang PH; Kulp SK; Chen CS
Pharmacol Res; 2017 Mar; 117():370-376. PubMed ID: 28077300
[TBL] [Abstract][Full Text] [Related]
11. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
12. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
[TBL] [Abstract][Full Text] [Related]
13. RAS-targeted therapies: is the undruggable drugged?
Moore AR; Rosenberg SC; McCormick F; Malek S
Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
[TBL] [Abstract][Full Text] [Related]
14. The reactivity-driven biochemical mechanism of covalent KRAS
Hansen R; Peters U; Babbar A; Chen Y; Feng J; Janes MR; Li LS; Ren P; Liu Y; Zarrinkar PP
Nat Struct Mol Biol; 2018 Jun; 25(6):454-462. PubMed ID: 29760531
[TBL] [Abstract][Full Text] [Related]
15. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
Chen H; Smaill JB; Liu T; Ding K; Lu X
J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
[TBL] [Abstract][Full Text] [Related]
16. Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
Wang Y; Kaiser CE; Frett B; Li HY
J Med Chem; 2013 Jul; 56(13):5219-30. PubMed ID: 23566315
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological targeting of RAS: Recent success with direct inhibitors.
O'Bryan JP
Pharmacol Res; 2019 Jan; 139():503-511. PubMed ID: 30366101
[TBL] [Abstract][Full Text] [Related]
18. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in cancer drug discovery targeting RAS.
Wilson CY; Tolias P
Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
[TBL] [Abstract][Full Text] [Related]
20. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.
Dhawan NS; Scopton AP; Dar AC
Nature; 2016 Sep; 537(7618):112-116. PubMed ID: 27556948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]